Developing a unique mRNA platform
Combined Therapeutics is an emerging mRNA medicines company developing a unique modified mRNA platform to protect vulnerable populations from global infectious diseases as well as to cure cancer.
Fueled by our proprietary technologies, which target protein expression to specific tissues while reducing off target effects, combined with an experienced team in delivery and mRNA-based therapeutics, we are committed to harnessing the body’s machinery to protect and improve patients’ lives.
Combined Therapeutics has developed a unique platform built around Multi Organ Protective (MOP) miRNA sequences combined to therapeutic mRNAs, that allow to target and focus therapeutic protein expression in specific tissues, spare healthy tissues and reduce off target effects.
Together with our partners, we are committed to using our platform to protect vulnerable populations from global infectious disease threats as well as to cure cancer.
Board of Directors
Mr. Matussiere has worked until 2017 and for more than twenty years as an investment banker for Société Générale, Citigroup and BNP Paribas, primarily out of London. His focus was on the sales and marketing of structured products, mainly in the credit space. Since 2017, Pierre has become an active Angel investor and fundraiser -through his FCA regulated company M Finance- focusing on sectors such as hospitality, leasing of transport equipment, Healthtech, residential and commercial properties and Biotech. Pierre graduated in 1995 from HEC in Paris.
President and Cofounder CEO, Board Director
Dr. Micol has been President and co-founder CEO of Combined Therapeutics since 2016. Previously, he held several positions across the Institut Mérieux group: ABlinc (USA), Shantha Biotechnics (India), Transgene (China and France). Dr. Micol is an entrepreneur with affiliations to six famous universities (MIT in US, LSE in UK, Paris VI, Paris V, Paris Dauphine in France and Global LBS in UK). Additionally he helped to set up the first reference center for primary immunodeficiency in France in 2005.
Romain Micol MD, MPH, PhD, MBA, LLM
President and CEO (cofounder), Leadership
Raffy Kazandjian, MBA
CTx SAS Managing Director, Leadership
Valérie Duval, PhD
Associate Director, Biology
Principal Scientist, Biology
Teddy Jégu, PhD
Project Manager, Biology
Kim Foster, MLS(ASCP)CM
Senior Research Associate, Biology
Lauren Speciner, PhD
Principal Scientist, Formulation & Process Development
Senior Research Associate, Formulation & Process Development
Senior Manager Strategy & Finance, Finance & Strategy
Paul Waldron, PhD
Patent Assistant, IP & Corporate Attorney
Advisors / Consultants
Thomas VanCott, PhD
Mark Tracy, PhD
Devenand Crease, PhD
Sarah Cooleybeck, J.D.
Robert Langer, ScD
Cofounder – Oncology / Virotherapy
Dan Anderson, PhD
Cofounder – Oncology / Virotherapy
David Neafus, MBA
Ronald E. Kaunfer, BSc
EXISTING Science LANDSCAPE
What are mRNA therapies
- Utilizes existing cell machinery to make therapeutic proteins that can treat disease
- Can be modified to produce therapeutic proteins only in the target cells, such as tumoral cells, and spare healthy tissue.
- Nucleic acids therapies are a very versatile platform as they can code for any protein of interest and are transient; broken down quickly after their job is done.
Our mRNA platform: Combined Therapeutics’ Drug and Modulation Platform (DMPCTx):
- A new generation of modified mRNA delivered in a lipid nanoparticle capable of targeted protein expression in specific tissues
- 3 routes of Administration: Intravenous, Intra-tumoral, Intramuscular
- 2 medical applications: Vaccines & Oncology
- Multi-Organ Protection (MOP): Treatment side effects occur when healthy cells are affected alongside diseased cells. MOP is key to delivering and focusing treatment to diseased cells only, thus preventing off target effects
Infectious disease – Prophylactic vaccine
- The success of mRNA vaccines in the global fight against COVID19 highlights the potential of this new class of medicines. RNA vaccines can be developed more rapidly than traditional vaccines to tackle infectious disease outbreaks and can be leveraged to direct the immune system more effectively against infectious diseases.
- We can use our unique approach to develop next generation vaccines. Our infectious disease vaccine candidates contain modified mRNA-encoding antigens to specifically activate an immune response, allowing the body to fend off future infections. At Combined Therapeutics we can deliver multiple mRNAs that encode for both an antigen and an immunomodulator. This dual approach boosts the immune response against the infection, leading to better disease protection
- Immunotherapy is a promising approach that bolsters the patient immune system to fight his own cancer. However, it can generate severe adverse effects and exhibits a low response rate, particularly in solid cancers with an immunosuppressive microenvironment.
- DMPCTx revolutionizes the treatment of solid tumors:
- Protect: Following a systemic administration of mRNA-based immunotherapy, DMPCTx safely produces therapeutic proteins in tumor cells only, fully sparing healthy tissues, reducing systemic toxicities and preserving safety
- Sensitize & Boost: DMPCTx platform can be harnessed as a companion boost to sensitize all tumors to any immunotherapeutic regimen, such as virotherapy, CAR T-cell therapy, and immune checkpoint inhibitors, and thus significantly enhance their efficacies
3/14/22 – 3/16/22
Combined Therapeutics is invited to attend Pierre Fabre Virtual Biopharma Partnering in March 2022 to showcase the company and our innovative therapeutics.
CTx has entered in a lease to build its own laboratory in Cambridge.
Edouard Hervey, former Goldman Sachs partner, who has become a special advisor to the CEO with a core focus on corporate strategy
Pallab Ghosh joins Combined Therapeutics as a Principal Scientist.
Paul Waldron joins Combined Therapeutics as Patent Assistant.
Teddy Jégu joins Combined Therapeutics as Project Manager.
Kim Foster joins Combined Therapeutics as Research Associate.